A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation

References

• Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43
   PubMed Web of Science ®Google Scholar
• Nishimura R, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Am Coll Cardiol 2014 (Epub ahead of print)
   Google Scholar
• de Marchena E, Badiye A, Robalino G, et al. Respective prevalence of the different carpentier classes of mitral regurgitation: a stepping stone for future therapeutic research and development. J Card Surg 2011;26:385-92
   PubMed Web of Science ®Google Scholar
• Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;52:e1-42
   PubMed Web of Science ®Google Scholar
• Jamieson WR, Cartier PC, Allard M, et al. Surgical management of valvular heart disease 2004. Can J Cardiol 2004;20(E Suppl):7E-120E
   Google Scholar
• Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68
   PubMed Web of Science ®Google Scholar
• Mirabel M, Iung B, Baron G, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 2007;28:1358-65
   PubMed Web of Science ®Google Scholar
• Borger MA, Alam A, Murphy PM, et al. Chronic ischemic mitral regurgitation: repair, replace or rethink? Ann Thorac Surg 2006;81:1153-61
   PubMed Web of Science ®Google Scholar
• Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2012;42:S1-44
   PubMed Web of Science ®Google Scholar
• Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381-7
   PubMed Web of Science ®Google Scholar
• McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2004;128:916-24
   PubMed Web of Science ®Google Scholar
• Lee LS, Kwon MH, Cevasco M, et al. Postoperative recurrence of mitral regurgitation after annuloplasty for functional mitral regurgitation. Ann Thorac Surg 2012;94:1211-16; discussion 6–7
   Google Scholar
• Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol 2008;52:319-26
   PubMed Web of Science ®Google Scholar
• Agricola E, Ielasi A, Oppizzi M, et al. Long-term prognosis of medically treated patients with functional mitral regurgitation and left ventricular dysfunction. Eur J Heart Fail 2009;11:581-7
   PubMed Web of Science ®Google Scholar
• Chiam PT, Ruiz CE. Percutaneous transcatheter mitral valve repair: a classification of the technology. JACC Cardiovasc Interv 2011;4:1-13
   PubMed Web of Science ®Google Scholar
• Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-406
   PubMed Web of Science ®Google Scholar
• Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 2013;62:317-28
   PubMed Web of Science ®Google Scholar
• Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 2012;59:130-9
   PubMed Web of Science ®Google Scholar
• Auricchio A, Schillinger W, Meyer S, et al. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 2011;58:2183-9
   PubMed Web of Science ®Google Scholar
• Franzen O, Baldus S, Rudolph V, et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J 2010;31:1373-81
   PubMed Web of Science ®Google Scholar
• Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation following transcatheter mitral valve repair with the MitraClip(R) System. J Am Coll Cardiol 2013 (Epub ahead of print)
   Google Scholar
• Rudolph V, Knap M, Franzen O, et al. Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol 2011;58:2190-5
   PubMed Web of Science ®Google Scholar
• Pleger ST, Mereles D, Schulz-Schonhagen M, et al. Acute safety and 30-day outcome after percutaneous edge-to-edge repair of mitral regurgitation in very high-risk patients. Am J Cardiol 2011;108:1478-82
   Google Scholar
• Schillinger W, Athanasiou T, Weicken N, et al. Impact of the learning curve on outcomes after percutaneous mitral valve repair with MitraClip and lessons learned after the first 75 consecutive patients. Eur J Heart Fail 2011;13:1331-9
   PubMed Web of Science ®Google Scholar
• Tamburino C, Ussia GP, Maisano F, et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J 2010;31:1382-9
   PubMed Web of Science ®Google Scholar
• Van den Branden BJ, Swaans MJ, Post MC, et al. Percutaneous edge-to-edge mitral valve repair in high-surgical-risk patients: do we hit the target? JACC Cardiovasc Interv 2012;5:105-11
   PubMed Web of Science ®Google Scholar
• Scandura S, Ussia GP, Caggegi A, et al. Percutaneous mitral valve repair in patients with prior cardiac surgery. J Card Surg 2012;27:295-8
   Google Scholar
• Neuss M, Schau T, Schoepp M, et al. Patient selection criteria and midterm clinical outcome for MitraClip therapy in patients with severe mitral regurgitation and severe congestive heart failure. Eur J Heart Fail 2013;15:786-95
   PubMed Web of Science ®Google Scholar
• Boekstegers P, Hausleiter J, Baldus S, et al. Percutaneous interventional mitral regurgitation treatment using the Mitra-Clip system. Clin Res Cardiol Off J Ger Card Soc 2013;103:85–96
   Google Scholar
• Schillinger W, Hunlich M, Baldus S, et al. Acute outcomes after MitraClip therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) Registry. EuroIntervention 2013;9:84-90
   PubMed Web of Science ®Google Scholar
• Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2012;14:1050-5
   PubMed Web of Science ®Google Scholar
• Rogers JH, Low RI. Noncentral mitral regurgitation: a new niche for the MitraClip. J Am Coll Cardiol 2013;62:2378-81
   Google Scholar
• Taramasso M, Maisano F, Latib A, et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention 2014 (Epub ahead of print)
   Google Scholar
• Yeo KK, Yap J, Yamen E, et al. Percutaneous mitral valve repair with the MitraClip: early results from the MitraClip Asia-Pacific Registry (MARS). EuroIntervention 2014 (Epub ahead of print)
   Google Scholar
• Reichenspurner H, Schillinger W, Baldus S, et al. Clinical outcomes through 12 months in patients with degenerative mitral regurgitation treated with the MitraClip(R) device in the ACCESS-EUrope Phase I trial. Eur J Cardiothorac Surg 2013;44:e280-8
   PubMed Web of Science ®Google Scholar
• Armoiry X, Brochet E, Lefevre T, et al. Initial French experience of percutaneous mitral valve repair with the MitraClip: a multicentre national registry. Arch Cardiovasc Dis 2013;106:287-94
   Google Scholar
• Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052-61
   PubMed Web of Science ®Google Scholar
• Chan PH, She HL, Alegria-Barrero E, et al. Real-world experience of MitraClip for treatment of severe mitral regurgitation. Circ J Off J Jpn Circ Soc 2012;76:2488-93
   Web of Science ®Google Scholar
• Wan B, Rahnavardi M, Tian DH, et al. A meta-analysis of MitraClip system versus surgery for treatment of severe mitral regurgitation. Ann Cardiothorac Surg 2013;2:683-92
   PubMedGoogle Scholar
• Microsoft Corporation. Redmond, Washington. Microsoft Excel. 2007
   Google Scholar
• Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2006
   Google Scholar
• Shroyer AL, Coombs LP, Peterson ED, et al. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Ann Thorac Surg 2003;75:1856-64; discussion 64–5
   PubMed Web of Science ®Google Scholar
• Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 1999;22:385-90
   Google Scholar
• Criteria Committee of the American Heart Association (New York City Affiliate). Nomenclature and criteria for diagnosis of disease of the heart and great vessels. 9th edn. Boston, MA: Little Brown & Co, 1994
   Google Scholar
• Abbott Vascular Structural Heart (Data on File). A Study of the Evalve® Cardiovascular Valve Repair (MitraClip® Endovascular Valve Edge-to-Edge) System (EVEREST II): EVEREST II High Risk Registry 3-Year Clinical Report. 2012
   Google Scholar
• Statistics Canada. Life Tables, Canada, Provinces and Territories 2000 to 2002, Catalogue no. 84-537-XIE. Ottawa: Health Statistics Division, 2006
   Google Scholar
• Göhler A, Geisler BP, Manne JM, et al. Utility estimates for decision-analytic modeling in chronic heart failure–health states based on New York Heart Association classes and number of rehospitalizations. Value Health 2009;12:185-7
   PubMed Web of Science ®Google Scholar
• Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 2000;9:149-58
   PubMed Web of Science ®Google Scholar
• McAlister FEJ, Wiebe N, Rowe B, et al. Cardiac resynchronization therapy for congestive heart failure. Evidence Report/Technology Assessment No. 106. (Prepared by the University of Alberta Evidence-based Practice Center) under Contract No. 290-02-0023. Rockville, MD: Agency for Healthcare Research and Quality, 2004
   Google Scholar
• Lewis EF, Johnson PA, Johnson W, et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001;20:1016-24
   PubMed Web of Science ®Google Scholar
• Holland R, Rechel B, Stepien K, et al. Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail 2010;16:150-6
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005;7:243-51
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20
   PubMed Web of Science ®Google Scholar
• Chaplin S, Scuffham PA, Alon M, et al. Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands. Neth Heart J 2004;12:331-6
   PubMedGoogle Scholar
• Marwick TH, Scuffham PA, Hunink MG. Selection for early surgery in asymptomatic mitral regurgitation: a Markov model. Int J Cardiol 2013;165(2):266-72
   Google Scholar
• Dr. Anita Asgar. Personal communication. 2013
   Google Scholar
• Ontario Case Costing Initiative. Costing Analysis Tool. 2013. Available from: www.occp.com
   Google Scholar
• Regier DA, Sunderji R, Lynd LD, et al. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 2006;174:1847-52
   PubMed Web of Science ®Google Scholar
• Resnic FS, Arora N, Matheny M, et al. A cost-minimization analysis of the angio-seal vascular closure device following percutaneous coronary intervention. Am J Cardiol 2007;99:766-70
   PubMed Web of Science ®Google Scholar
• Tretiak R, Laupacis A, Riviere M, et al. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. CMAJ 1996;154:1501-8
   Google Scholar
• Comay D, Marshall JK. Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study. Can J Gastroenterol 2002;16:677-82
   PubMedGoogle Scholar
• Sunnybrook Health Sciences Center. Freedom of Information Request 2013-0009-FOI. 2013
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario: Schedule of Benefits for Laboratory Services. 1999
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario: Schedule of Benefits for Physician Services. 2013
   Google Scholar
• Treede H, Schirmer J, Rudolph V, et al. A heart team's perspective on interventional mitral valve repair: percutaneous clip implantation as an important adjunct to a surgical mitral valve program for treatment of high-risk patients. J Thorac Cardiovasc Surg 2012;143:78-84
   PubMed Web of Science ®Google Scholar
• Conradi L, Treede H, Franzen O, et al. Impact of MitraClip therapy on secondary mitral valve surgery in patients at high surgical risk. Eur J Cardiothorac Surg 2011;40:1521-6
   PubMed Web of Science ®Google Scholar
• Mealing S, Feldman T, Eaton J, et al. EVEREST II high risk study based UK cost-effectiveness analysis of MitraClip(R) in patients with severe mitral regurgitation ineligible for conventional repair/replacement surgery. J Med Econ 2013;16:1317-26
   PubMedGoogle Scholar
• Mealing SE, Eaton J. TCT-795 Abstract: MitraClip for patients with mitral regurgitation who are ineligible for surgical repair or replacement: a UK based cost-utility analysis. J Am Coll Cardiol 2011;58:B212-B
   Google Scholar
• Mealing SE, Eaton J, Singh M, et al. TCT-795 Poster: MitraClip for patients with mitral regurgitation who are ineligible for surgical repair or replacement: a UK based cost-utility analysis. Presented at the Transcatheter Cardiovascular Therapeutics annual scientific symposium, San Francisco, California, November 7-11, 2011
   Google Scholar
• Evalve, Abbott Vascular. United States Food and Drug Administration. MitraClip Clip Delivery System – P100009 Device Approval. Silver Sprint, MD: Food and Drug Administration. Available online at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm375149.htm. Accessed January 25, 2014
   Google Scholar
• Cardiovascular outcomes assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients (COAPT). NCT01626079. Bethesda, MD: National Library of Medicine (US). 2014. Available online at: http://clinicaltrials.gov/ct2/show/NCT01626079. Accessed January 25, 2014
   Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-42
   PubMed Web of Science ®Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81
   PubMed Web of Science ®Google Scholar
• British Columbia Ministry of Health Services. British Columbia PharmaCare Formulary. Available online at: http://www.health.gov.bc.ca/pharmacare/benefitslookup/faces/Search.jsp. Accessed January 14, 2014
   Google Scholar